ProMIS Neurosciences Inc.
PMN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PMN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PMN
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company developing antibody therapeutics for neurodegenerative diseases, with its lead candidate PMN310 targeting toxic oligomers of amyloid-beta in Alzheimer's disease. The company has completed a Phase 1a single-ascending-dose study and is conducting a Phase 1b multiple-ascending-dose study, while facing ongoing net losses and a need for additional financing to sustain operations.
Key risk: Need for additional financing
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for ProMIS Neurosciences Inc..
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company developing antibody therapeutics for neurodegenerative diseases, with its lead candidate PMN310 targeting toxic oligomers of amyloid-beta in Alzheimer's disease. The company has completed a Phase 1a single-ascending-dose study and is conducting a Phase 1b multiple-ascending-dose study, while facing ongoing net losses and a need for additional financing to sustain operations.
- Lead candidate PMN310 is a monoclonal antibody designed to selectively target toxic oligomers of amyloid-beta for Alzheimer's disease [sec_mda · as of 2026-08-13].
- Completed a Phase 1a single-ascending-dose study (NCT06105528) and is conducting a Phase 1b multiple-ascending-dose study (NCT06750432) as of the latest catalyst timeline [catalyst].
- Reported cash and equivalents of $53.4M as of June 30, 2026, with net income of -$11.7M for the three months ended June 30, 2026 [sec].
- Accumulated deficit of $150.4M as of June 30, 2026, and negative cash flows from operations of $22.8M for the six months ended June 30, 2026 [sec_mda · as of 2026-08-13].
- Expects existing cash to fund operating expenses and capital expenditure requirements through 2027, but may need additional funding to initiate further clinical trials [sec_mda · as of 2026-08-13].
What works
- Lead candidate PMN310 targets toxic oligomers of amyloid-beta, a mechanism that may offer a differentiated approach in Alzheimer's disease [sec_mda · as of 2026-08-13].
- Completed a Phase 1a study and is advancing a Phase 1b multiple-ascending-dose study, indicating progress in clinical development [catalyst].
- Raised $70.1 million in net proceeds from a private placement in January 2026, providing a cash runway through 2027 [sec_mda · as of 2026-05-12].
What to weigh
- Has not generated any revenue to date and expects to continue incurring net losses for the foreseeable future [sec_mda · as of 2026-08-13].
- Accumulated deficit of $150.4M as of June 30, 2026, with negative cash flows from operations of $22.8M for the six months ended June 30, 2026 [sec_mda · as of 2026-08-13].
- Additional funding will be necessary to initiate further clinical trials or programs, and there is no assurance of obtaining such financing on acceptable terms [sec_mda · as of 2026-08-13].
- Shareholders' equity was negative $1.3M as of June 30, 2026, indicating a deficit in equity [sec].
From the filings
Quoted directly from source documents.
The company has not generated revenues and expects continued losses.
“We are a development stage company as we have not generated revenues to date and do not expect to have significant revenues until we are able to sell a product candidate after obtaining applicable regulatory approvals”
SEC MD&A · May 12, 2026
Cash runway is estimated through 2027 based on current operating plan.
“Based on our current operating plan, we expect that our existing cash, including the proceeds from January 2026, will be sufficient to fund our operating expenses and capital expenditure requirements through 2027.”
SEC MD&A · August 13, 2026
The company reported an accumulated deficit of $150.4 million as of June 30, 2026.
“reported an accumulated deficit of $150.4 million as of June 30, 2026”
SEC MD&A · August 13, 2026
Phase 1b multiple-ascending-dose study of PMN310 is active but not recruiting.
“A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerabil - NCT: NCT06750432. Status: Active, not recruiting.”
Catalysts
Catalyst timeline
- 2023-11-18 · Phase 1a Start (PMN310) — A Phase 1a, double-blind, placebo-controlled, single ascending dose study of PMN310; status is completed.
- 2024-12-13 · Phase 1b Start (PMN310) — A Phase 1b, double-blind, placebo-controlled, multiple ascending dose study of PMN310; status is active, not recruiting.
Risks & what to watch (4)›
Key risks
- Need for additional financing — Additional funding will be necessary to fund future clinical activities and pay existing liabilities; no assurance of success [sec_mda · as of 2026-08-13].
- History of net losses — Incurred net losses of $11.7M and $20.0M for the three and six months ended June 30, 2026 [sec_mda · as of 2026-08-13].
- Negative shareholders' equity — Shareholders' equity was negative $1.3M as of June 30, 2026 [sec].
- Dependence on clinical trial success — Product candidates are in early-stage development; failure could delay or eliminate commercialization [sec_mda · as of 2026-08-13].
What to watch
- Initiation of any additional clinical trials or programs beyond the current Phase 1b study [sec_mda · as of 2026-08-13].
- Ability to secure additional funding through public/private financings, collaborations, or licensing agreements [sec_mda · as of 2026-08-13].
- Progress and results from the Phase 1b multiple-ascending-dose study of PMN310 (NCT06750432) [catalyst].
- Changes in cash runway and operating expenses as the company advances its pipeline [sec_mda · as of 2026-08-13].
Sources: Catalysts · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run ProMIS Neurosciences Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ProMIS Neurosciences Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
15.7 months
D/E 0.15 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
5 buys · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
20
Total value held
$68.8M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 2,585,514 | $32.8M |
| deep track capital, lp | 835,655 | $10.6M |
| wellington management group llp | 696,378 | $8.8M |
| great point partners llc | 371,402 | $4.7M |
| sphera funds management ltd. | 325,591 | $4.1M |
| adage capital partners gp, l.l.c. | 139,275 | $1.8M |
| adar1 capital management, llc | 95,350 | $1.2M |
| 683 capital management, llc | 92,850 | $1.2M |
| millennium management llc | 77,921 | $990K |
| empery asset management, lp | 60,353 | $766K |
Showing top 10 of 20 institutional holders of ProMIS Neurosciences Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 1.6%
- Days to cover
- 3.5
- Shares short
- 138,078
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PMN short interestGovernance
Frequently asked questions
What is the AI investment thesis for ProMIS Neurosciences Inc.?
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company developing antibody therapeutics for neurodegenerative diseases, with its lead candidate PMN310 targeting toxic oligomers of amyloid-beta in Alzheimer's disease. The company has completed a Phase 1a single-ascending-dose study and is conducting a Phase 1b multiple-ascending-dose study, while facing ongoing net losses and a need for additional financing to sustain operations.
What is ProMIS Neurosciences Inc.'s lead drug candidate?
ProMIS Neurosciences Inc.'s most advanced tracked candidate is pmn310 (Phase 1) for Alzheimer Disease, Early Onset; Healthy Participants.
Who is the CEO of ProMIS Neurosciences Inc.?
Mr. Neil K. Warma M.B.A. is the chief executive officer of ProMIS Neurosciences Inc. (PMN).
Where is ProMIS Neurosciences Inc. headquartered?
ProMIS Neurosciences Inc. (PMN) is headquartered in Toronto, ON, Canada.
What therapeutic areas does ProMIS Neurosciences Inc. focus on?
ProMIS Neurosciences Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.